Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Journal Medical Informatics Technology Indonesian Journal of Biomedicine and Clinical Sciences
Hariftyani, Arisvia Sukma
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Computer Science & IT Dentistry Engineering Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Low Tuberculosis Screening among Household Family Members of Tuberculosis Patients in Banyuarang and Sidowarek Farid, Muhammad Rifqo Hafidzudin; Rananda, Arif; Aflahudin, Muhammad Ahda Naufal; Musalim, Dian Anggraini Permatasari; Hariftyani, Arisvia Sukma; Hanani, Nadya Kelfinta; Rofiq, Rodia Amanata; Aulia, Shazia Hafazhah; Sidqoh, Aida Badi’atus; Hewiz, Alya Shafira
Journal Medical Informatics Technology Volume 1 No. 4, December 2023
Publisher : SAFE-Network

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37034/medinftech.v1i4.19

Abstract

Early tuberculosis detection is vital, necessitating widespread screening. The WHO's End Tuberculosis strategy aims to combat this epidemic. Active screening is critical for identifying asymptomatic individuals at risk. Data from Pulorejo Primary Health Center, Jombang, indicates a low 10% coverage of suspected cases in 2021, particularly among household contacts, resulting in continued transmission, late detection, post-treatment symptoms, and even death. Therefore, this study was conducted to determine the number of screening participation of households of tuberculosis patients in Banyuarang and Sidowarek Village. This research is a descriptive observational. The data collected was primary data from questionnaires. The study population consisted of households of tuberculosis patients in the Banyuarang and Sidowarek Villages, Jombang Regency. Data collected from 12 respondents showed the prevalent characteristics among the 12 respondents were predominantly female, adult age, high school education, working, limited knowledge about tuberculosis, and easy access to healthcare services. Among the 12 respondents in Banyuarang and Sidowarek, 9 respondents had never been screened, while 3 respondents had undergone screening. The primary reasons for respondents not undergoing screening were lack of awareness regarding the necessity of screening and busy schedules.
Safety and efficacy of ontamalimab in inflammatory bowel disease: A systematic review and dose- response meta-analysis Setyobudi, Assyadilla Kirana; Yudianto, Valentino Ryu; Hariftyani, Arisvia Sukma; Gatot Soegiarto
Indonesian Journal of Biomedicine and Clinical Sciences Vol 57 No 4 (2025)
Publisher : Published by Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/inajbcs.v57i4.20500

Abstract

Inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, involve chronic inflammation of the digestive tract. The incidence of IBD has been increasing globally, posing a growing burden despite advancements in treatment. Novel therapies targeting adhesion molecules such as MAdCAM-1 show promise by specifically inhibiting lymphocyte infiltration into the gut, potentially offering safer and more effective treatment options. This meta-analysis and systematic review were conducted to provide efficacy and safety analysis of ontamalimab for IBD treatment. Dose-response (DRMA), network (NMA), and random effect meta-analysis were conducted to extract clinical response, clinical remission, biomarker change, and adverse events of ontamalimab. Studies were retrieved from PubMed, Cochrane, and EMBASE to describe the pooled risk ratio (RR) and heterogeneity was determined if I2 >50%. RoB2 tool and ROBINS-I were used to assess risk of bias in RCT and clinical trial studies, respectively. The result was considered significant if p<0.05. A total of 670 studies were screened, resulting in 8 multicentre studies. There were significant differences in clinical response (RR: 1.39; 95%CI: 1.12–1.73; p = 0.003; I2= 35%), clinical remission (RR: 1.72; 95%CI: 1.17–2.53; p=0.006; I2= 26%), mean change of FC (RR: 624.29; 95%CI: 543.28-705.29; p<0.001; I2= 0%), mean change of CRP serum (RR: 9.71; 95%CI: 7.12–12.3; p<0.001), and mean MAdCAM-1 serum level (RR: 235.57; 95%CI: 203.80–267.33; p <0.001) between ontamalimab 75 mg and placebo after 12 wk of treatment. Meanwhile, adverse events from both groups were similar to those observed in patients treated with either placebo or ontamalimab. This study concluded that ontamalimab 75mg demonstrated significant efficacy in treating IBD, achieving superior outcomes in clinical response and clinical remission compared to placebo. Importantly, no cases of PML and significant adverse events were detected, indicating a favorable safety profile relative to other anti-MAdCAM-1 therapies.
Co-Authors Aflahudin, Muhammad Ahda Naufal Aulia, Shazia Hafazhah Farid, Muhammad Rifqo Hafidzudin Gatot Soegiarto Hanani, Nadya Kelfinta Hewiz, Alya Shafira Musalim, Dian Anggraini Permatasari Rananda, Arif Rofiq, Rodia Amanata Setyobudi, Assyadilla Kirana Sidqoh, Aida Badi’atus Yudianto, Valentino Ryu